Phase 1 study of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
Phase of Trial: Phase I
Latest Information Update: 23 Apr 2018
At a glance
- Drugs Nalmefene (Primary)
- Indications Opioid abuse
- Focus Adverse reactions
- 23 Apr 2018 As the MR talks about the results and based on company pipeline I have assumed trial status as completed. Patients assumed as Volunteers.
- 18 Apr 2018 According to Opiant Pharmaceuticals media release, the company has been awarded a grant of approximately $7.4 million from the National Institutes of Healths National Institute on Drug Abuse (NIDA) for the development of OPNT003 (intranasal nalmefene), the grant follows encouraging data from this study.
- 20 Feb 2018 New trial record